Massimiliano (max) Bianchi PhD

Max joined Transpharmation in January 2014 as General Manager of the Irish subsidiary Transpharmation Ireland Ltd, a Campus Company at the Trinity College Dublin – Institute of Neuroscience (TCIN). Dr. M. Bianchi has 15 years of research experience on neuropharmacology, neuronal plasticity and drug discovery. He has been associated for six years with the former Psychiatry Centre of Excellence for Drug Discovery of GlaxoSmithKline (Psychiatry CEDD-GSK). During such period Max successfully completed is PhD on the neuropsychopharmacology of cytoskeletal microtubules (University of Nottingham, UK) and worked as scientist in the Neurochemistry team of the Psychiatry CEDD-GSK. He managed an innovative project of target validation showing that animal models of depression and antidepressant drugs can influence neuronal plasticity and the expression and function of specific microtubular proteins.

He then joined the French Biotech MAPREG in 2007 to establish and lead a new psychopharmacology unit. He designed and successfully managed an innovative drug discovery EU granted project (Eurostars/Eureka) named DEPSTER (E!5291): “The pregnenolone-derivative 3beta-methoxy-pregnenolone as a new therapy for the treatment of depressive disorders: a preclinical project”. Max’s innovative experimental approaches are multidisciplinary and couples animal models, behavioural assays, molecular biology and experimental medicine.